Onxeo designs and develops innovative drugs with unique mechanisms of action in rare and orphan cancers, with a focus on DNA-targeting and resistance to existing treatments.
iQone Healthcare, as part of the Clinigen group, offers market access services accross Europe. We collaborate with reliable and reputed partners to distribute specialty compounds in oncology, hematology and rare diseases.
iQone Healthcare Group is dedicated to oncology, haematology and rare diseases and offers Early Access Program (EAP) in partnership with Onxeo.
We strive for effectiveness by taking fast decisions which are transparent and consistent. We are responsive to demands and flexible in solving them.
In addition, our medical and scientific expertise enables us to select and offer products of the highest repute.